Meta-iodobenzylguanidine (m-IBG) is a biogenic amine precursor, noradrenaline analogue, which is actively taken up by tumors. In tracer amounts, [123/131I]-m-IBG is used as a radiopharmaceutical to target normal and malignant tissues of neuroadrenergic origin for diagnostic scintigraphy, and labeled with higher activities of 131I, it is used for therapy of phenochromocytoma and neuroblastoma. The increased clinical therapeutic use of unlabeled m-IBG at doses of up to 40 mg/m2 emphasizes the need for syntheses and an established quality protocol for this substance that relies on verifiable analytical parameters. Evaluation of radioiodination was necessary to obtain higher labeling yield (we achieved over 90% instead no more than 70%), because isotopic exchange labeling of m-IBG with 131I catalyzed by Cu(I) is much more efficient than with conveniently used ammonium sulphate.Physical chemistry 2006 : 8th international conference on fundamental and applied aspects of physical chemistry; Belgrade (Serbia); 26-29 September 200
